Hepatitis B Surface Antibody
Label Mnemonic: HBSAB
Epic Lab Code: LAB619
Downtime Form: A-1a General Laboratory Requisition
Chemistry
6240 RCP
356-3527
Specimen(s):
Plasma
Collection Medium:
Plasma Separator Tube 4.5 mL
Alternate Collection Media:
Call laboratory for additional acceptable specimen collection containers.
Minimum:
3 mL whole blood from light green top tube or TWO Microtainer® devices for pediatric patients
Testing Schedule:
24 hrs/day, 7 days a week, including holidays.
Turn Around Time:
1 hour (upon receipt in laboratory)
Reference Range:
Non-reactive; positive with vaccine administration. Non-reactive samples have anti-HBs level less than 8.5 mIU/mL. Reactive samples have anti-HBs level greater than or equal to 11.5 mIU/mL. The result is indeterminate if the sample tests twice with anti-HBs results greater than or equal to 8.5 mIU/mL but less than 11.5 mIU/mL.
Comments:
Part of initial diagnostic hepatitis profile or to verify immunity status in patients who have received the hepatitis B vaccine. Results include reactivity (REACTIVE or NON-REAC), immune status (IMMUNE or NON IMM OR INDETERM) and quantitative concentration. Anti-HBs can be formed following a hepatitis B infection or after hepatitis B vaccination.

This test is also performed in the Iowa River Landing (IRL) clinical laboratory (for specimens drawn at that site).
Test Limitations:
Assay is unaffected by icterus (<60 mg/dL), hemolysis (Hb < 1600 mg/dL), and lipemia (triglycerides < 1500 mg/dL). In patients receiving high biotin doses (> 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration. No false negative findings due to the high-dose hook effect are observed up to an anti-HBs concentration of 115,000 mIU/mL. In rare cases, interference due to extremely high titers of antibodies to analyte- specific antibodies, streptavidin, or ruthenium can occur.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination, and other findings. The assay is not intended for use in screening blood bank donors. A nonreactive test result does not exclude the possibility of exposure to or infection with hepatitis B. Individuals who have received blood component therapy, e.g., whole blood, plasma, immune globulin administration, during the previous 3 to 6 months may have a false reactive anti-HBs due to passive transfer of anti-HBs. Results from immunosuppressed individuals should be interpreted with caution.
Methodology:
Electrochemiluminescence Immunoassay (ECLIA)
CPT Code:
86706